dementia-2016_scientifictracks-abstracts

18 / 46

Notes:
Page 37
Dementia 2016
September 29-October 01, 2016
Volume 6 Issue 5(Suppl) J Alzheimers Dis Parkinsonism 2016
ISSN:2161-0460 JADP, an open access journal
conferenceseries .com
September 29-October 01, 2016 London, UK
5th International Conference on
Alzheimer’s Disease & Dementia
Krishna Prasad Pathak, J Alzheimers Dis Parkinsonism 2016, 6:5(Suppl)
Rivastigmine and Citalopram treatment for Alzheimer’s disease (AD) in daily clinical practice
Krishna Prasad Pathak
Amity Global Education, Nepal
Background: Pharmacological treatment for AD and depression are unfortunately few and of limited efficacy to cure the
disease.
Objectives: To assess the combined effects of rivastigmine and citalopram on Alzheimer's Disease.
Methods: Longitudinal clinical prospective study with 1278 AD patients on rivastigmine 9,5mg/patch and citalopram 20-40
mg/day over 48 months was assessed on the basis of DSM-IV, NINCDS-ADRDA, MMSE, FRSSD, GDS, HRS-D and follow up
of the patients.
Results: Four years after the baseline assessment, there were no significant differences in MMSE, Geriatric depression scale
and Hamilton rating scale for depression between patients treated with rivastigmine alone or combined rivastigmine with
citalopram with or without depression (p>0.05). Functional Rating Scale for symptoms of dementia, Activities of Daily Living
of patients with AD and depression treated with rivastigmine was significantly worse than patients treated with rivastigmine
and no depression (p=0.027).
Conclusions: The combination of rivastigmine and citalopram had no better results than rivastigmine alone in patients with
AD.
Biography
Krishna prasad pathak has completed PhD at the age of 35 years from Macedoniya university and doing research work on demenita issue in Nepal. He is the
lecturer of Amity Global education , kathmandu Nepal. He has published some papers in reputed journals and has been serving as an editorial board member.